Skip to content

Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial

B. Pradhan, Irving W. Wainer, Ruin Moaddel, M. Torjman, Michael S. Goldberg, M. Sabia, Tapan Parikh, A. Pumariega

July 1, 2017 DOI: 10.4103/2542-3932.211589 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized, placebo-controlled, cross-over clinical study
Sample size 10
Population Patients with chronic and refractory post-traumatic stress disorder (PTSD)
Interventions (R S)-ketamine TIMBER psychotherapy
Dose 0.5 mg/kg
Duration 12 TIMBER sessions (3 in first week, then 9 weekly); 18-month follow-up
Measures PTSD Checklist (PCL), Clinician Administered PTSD Scale for DSM-IV (CAPS), 17-item Hamilton Rating Scale for Depression (Ham-D-17), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MoCA), Assessment Scale for Mindfulness Interventions
Topics Depression Esketamine Ketamine Meditation PTSD
Registration NCT02766192
Key points Nine of ten patients with chronic, refractory PTSD showed robust improvement on PTSD, depression, and anxiety measures after 12 TIMBER sessions combined with either ketamine or placebo, with responses lasting about 32 days on average. Ketamine plus TIMBER produced a numerically longer response than placebo plus TIMBER (33 vs. 25 days), but this difference was not statistically significant. After switching from placebo to ketamine, patients' responses were significantly prolonged (49 vs. 25 days). The authors conclude that TIMBER augmented with low-dose (R,S)-ketamine may prolong ketamine's therapeutic effects and could be a valuable treatment option for PTSD.

Abstract

Background and

Objectives: Trauma memories lay at the core in etiopathogenesis of post-traumatic stress disorder (PTSD). Using pharmacological and cognitive behavioral treatments that specifically target trauma memories can improve the outcome. Ketamine has been shown to rapidly improve symptoms in PTSD and comorbid depression, but unfortunately these effects are short-lived. Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy is a type of mindfulness based cognitive behavioral therapy that targets the trauma memories. TIMBER psychotherapy in combination with (R,S)-ketamine are increasingly used to treat PTSD and comorbid depression. This study aims to determine if the combination of (R,S)-ketamine chemotherapy and TIMBER psychotherapy would produce a positive synergistic response in patients with PTSD.

Design: This is a randomized, placebo-controlled, cross-over clinical study.

Methods: Because response to ketamine alone is short-lived, this study combined TIMBER with a single infusion of 0.5 mg/kg (R,S)-ketamine to sustain its therapeutic effects. Ten patients with chronic and refractory PTSD were randomly assigned to two groups (n = 5 each): TIMBER-K group patients received ketamine infusion in combination with 12 TIMBER sessions (3 sessions in the first week followed by 9 sessions conducted on a weekly basis) and TIMBER-P group patients received placebo (normal saline infusion) in combination with 12 TIMBER sessions. The patients in the TIMBER-P group were switched to those in the TIMBER-K group after they experienced a sustained relapse. Outcome measures: PTSD Checklist (PCL), Clinician Administered PTSD Scale for DSM-IV (CAPS), the 17-item Hamilton Rating Scale for Depression (Ham-D-17, clinician rated), Beck Anxiety Inventory (BAI), and Montreal Cognitive Assessment (MoCA) at baseline and 8 hours after infusion were used to investigate if ketamine selectively affected trauma memories leaving the general memory intact. The mindfulness interventions in TIMBER were personalized based on subject's scores on Assessment Scale for Mindfulness Interventions which was administered at baseline, and after 5 sessions and 9 sessions (completion) of TIMBER. In this study, scores on CAPS and PCL scales were the primary outcome measures.

Results: In the acute phase trial ( first 3 months after infusion), nine out of 10 subjects showed robust response in primary outcome measures (PCL and CAPS scores for PTSD) and in the secondary outcome measures (Ham-D-17 and Beck Anxiety Inventory for depression and anxiety respectively) with a sustained response of 31.78 ± 18.29 days. The TIMBER-K group had a more sustained response (33 ± 22.98 days) compared to the TIMBER-P group (25 ± 16.8 days, P = 0.545). After switch from TIMBER-P group to TIMBER-K, patients experienced significantly prolonged response (49 vs. 25 days, P = 0.028). There were no intolerable side effects or dropouts during the 18-month follow-up period.

Conclusion: TIMBER psychotherapy augmented with low dose (R,S)-ketamine prolongs the therapeutic effects of the later and may be a valuable treatment option for PTSD.

Trial Registration: ClinicalTrials.gov identifier: NCT02766192

Comparable studies

Other randomized controlled trials on ketamine for PTSD, most cited first.

Study Year Design Participants
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder Patients with chronic PTSD related to a range of trauma exposures 2014 Randomized controlled trial n = 41
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Individuals with chronic PTSD 2021 Randomized controlled trial n = 30
Long term structural and functional neural changes following a single infusion of Ketamine in PTSD Individuals diagnosed with PTSD 2023 Randomized controlled pilot trial n = 27
d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. Patients with post-traumatic stress disorder (PTSD) 2018 Pilot randomized placebo-controlled study n = 20
Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol. Veterans with PTSD 2024 Randomized controlled trial n = 100

Citations in the library

Explore topics

By condition and practice